secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001193125-23-268165
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Q3 net loss $53.0M; cash $519.5M; navacaprant Phase 3 on track
----------------------------------------------------------------------

- Net loss of $53.0M in Q3 2023 vs. $29.3M in Q3 2022, driven by higher R&D costs ($41.6M vs. $22.5M).
- Cash, cash equivalents and marketable securities of $519.5M as of Sept 30, 2023; expected to fund operations into 2026.
- Navacaprant (KOR antagonist) Phase 3 KOASTAL trials ongoing; KOASTAL-1 topline data expected H2 2024; bipolar depression trial planned H1 2024.
- Completed IPO in Sept 2023; shares began trading on Nasdaq under NMRA; raised over $850M since inception.
- Appointed Robert Lenz, M.D., Ph.D., as EVP, head of R&D in October 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312523268165/0001193125-23-268165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312523268165/d518702d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer